Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose
- PMID: 1470224
- DOI: 10.1007/BF00169009
Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose
Abstract
Alloxan inhibited aconitase with a half maximal inhibitory concentration of 0.5 mM in sonically disrupted and 2.3 mM in intact isolated liver mitochondria. For dialuric acid the half maximal inhibitory concentrations were 1.1 mM and 2.5 mM, respectively. Ninhydrin and N-ethylmaleimide (NEM) also inhibited aconitase with half maximal inhibitory concentrations in the submillimolar range and t-butylhydroperoxide (BuOOH) in the millimolar range, which, however, were not different for disrupted and intact mitochondria. Only the aconitase substrate citrate, but not glucose provided protection of the enzyme against inhibition. In intact liver cells the half maximal inhibitory concentration for alloxan was 6.8 mM. Again, dialuric acid and BuOOH were less potent inhibitors while ninhydrin and NEM were more potent inhibitors of aconitase in intact liver cells. In intact liver cells, glucose and 3-O-methylglucose, but not mannoheptulose and citrate provided protection against alloxan inhibition. The results show that aconitase is not an enzyme particularly sensitive towards alloxan inhibition and thus apparently not a primary site for mediation of alloxan toxicity as it is the glucokinase. This makes a primary site of alloxan action in the mitochondria extremely unlikely. On the other hand the results demonstrate that both the intact mitochondrial and plasma membrane as uptake barriers provide protection against alloxan toxicity. In addition the results clearly show, that 3-O-methylglucose provides protection against alloxan action only at the level of the plasma membrane through inhibition of alloxan uptake into the cell, while the site of protection of mannoheptulose is only the sugar binding site of the glucokinase. In contrast, glucose is shown here to be the only sugar with a dual protective effect both through inhibition of alloxan uptake through the plasma membrane like 3-O-methylglucose and through protection of the glucokinase sugar binding site against alloxan inhibition of the enzyme like mannoheptulose. In the light of these results the unique protective potency of glucose as compared to that of other sugars is not surprising.
Similar articles
-
Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition.Br J Pharmacol. 1988 Nov;95(3):851-9. doi: 10.1111/j.1476-5381.1988.tb11714.x. Br J Pharmacol. 1988. PMID: 3207996 Free PMC article.
-
Effects of alloxan and ninhydrin on mitochondrial Ca2+ transport.Mol Cell Biochem. 1992 Dec 16;118(2):141-51. doi: 10.1007/BF00299393. Mol Cell Biochem. 1992. PMID: 1293509
-
Contrasting modes of action of D-glucose and 3-O-methyl-D-glucose as protectors of the rat pancreatic B-cell against alloxan.Biochim Biophys Acta. 1983 Feb 16;762(1):36-43. doi: 10.1016/0167-4889(83)90114-3. Biochim Biophys Acta. 1983. PMID: 6338936
-
Alloxan effects on mitochondria in vitro, studied with regard to inhibition of mitochondrial aconitase.Diabete Metab. 1985 Aug;11(4):232-7. Diabete Metab. 1985. PMID: 4043490
-
Alloxan toxicity to the pancreatic B-cell. A new hypothesis.Biochem Pharmacol. 1982 Nov 15;31(22):3527-34. doi: 10.1016/0006-2952(82)90571-8. Biochem Pharmacol. 1982. PMID: 6758791 Review. No abstract available.
Cited by
-
The mechanisms of alloxan- and streptozotocin-induced diabetes.Diabetologia. 2008 Feb;51(2):216-26. doi: 10.1007/s00125-007-0886-7. Epub 2007 Dec 18. Diabetologia. 2008. PMID: 18087688 Review.
-
Rodent animal models: from mild to advanced stages of diabetic nephropathy.Inflammopharmacology. 2014 Oct;22(5):279-93. doi: 10.1007/s10787-014-0215-y. Epub 2014 Aug 23. Inflammopharmacology. 2014. PMID: 25149089 Free PMC article. Review.
-
Studies on the cytotoxic, biochemical and anti-carcinogenic potentials of ninhydrin on Ehrlich ascites carcinoma cell-bearing Swiss albino mice.Invest New Drugs. 2000 Aug;18(3):221-30. doi: 10.1023/a:1006465504723. Invest New Drugs. 2000. PMID: 10958590